569250-U

Discovery^® HS C18 (3 µm) HPLC Columns

L × I.D. 5 cm × 4.6 mm, HPLC Column

• Sinónimos: Discovery RP18 HPLC Column
• Código UNSPSC: 41115700
• eCl@ss: 32110501
• NACRES: SB.52

Propiedades

• Nombre del producto: Columna para HPLC Discovery^® HS C18, 3 μm particle size, L × I.D. 5 cm × 4.6 mm
• Materiales: stainless steel column
• Agency: suitable for USP L1
• Línea del producto: Discovery^®
• Características: endcapped
• fabricante / nombre comercial: Discovery^®
• envase: 1 ea of
• Extensión del etiquetado: 20% Carbon loading
• Parámetros: ≤70 °C temp. range; 400 bar pressure (5801 psi)
• técnicas: HPLC: suitable; LC/MS: suitable
• L × D.I.: 5 cm × 4.6 mm
• superficie: 300 m²/g
• cobertura de la superficie: 3.2 μmol/m²
• impurezas: <10 ppm metals
• Matriz: silica gel, high purity, spherical particle platform; fully porous particle
• grupo activo de la matriz: C18 (octadecyl) phase
• tamaño de partícula: 3 μm
• tamaño de poro: 120 Å
• Intervalo de pH operativo: 2-8
• aplicaciones: food and beverages
• técnica de separación: reversed phase

Descripción

Aplicación

• A stability indicating RP-HPLC method for determination of the COVID-19 drug molnupiravir applied using nanoformulations in permeability studies.: This study developed a robust RP-HPLC method to determine molnupiravir in various nanoformulations, showcasing its potential application in permeability studies and ensuring drug stability (Reçber et al., 2022) (Reçber et al., 2022).


• Analysis of terizidone in plasma using HPLC-UV method and its application in a pharmacokinetic study of patients with drug-resistant tuberculosis.: This research presented an HPLC-UV method for analyzing terizidone in plasma, facilitating its use in pharmacokinetic studies of patients with drug-resistant tuberculosis (Mulubwa and Mugabo, 2018) (Mulubwa and Mugabo, 2018).


• Optimization of LC method for the quantification of doxorubicin in plasma and urine samples in view of pharmacokinetic, biomedical and drug monitoring therapy studies.: The study optimized an LC method for quantifying doxorubicin in plasma and urine, crucial for pharmacokinetic, biomedical, and drug monitoring therapy applications (Maliszewska et al., 2018) (Maliszewska et al., 2018).

Características y beneficios

• Stable, low bleed for LC-MS applications
• Scalable from analytical to preparatory
• Highly stable to ensure excellent run-to-run and lot-to-lot repducibility
• Higher hydrophobicity for better resolution of difficult analytes

   

Productos recomendados

Discover LiChropur reagents ideal for HPLC or LC-MS analysis

Información legal

Discovery is a registered trademark of Merck KGaA, Darmstadt, Germany